Berlin, Germany, June 7, 2017 – NOXXON Pharma N. V. (Alternext Paris : ALNOX), a biopharmaceutical company developing mainly in treatments against cancer, today announces that its Annual General Meeting (” AGM “) will be held at 13:30 h (CET) on June 27, 2017 at the offices of Freshfields Bruckhaus Deringer LLP, Strawinskylaan 10, 1077 XZ Amsterdam (the netherlands).
Download the free guide
Boost your gains
The financial statements of the fiscal year 2016, including the annual report, a formal notice convening the AGM, the agenda of the AGM, explanatory notes attached to the agenda, the instructions relating to the participation in the AGM and to vote, as well as other documents relating to the AGM, are now available to the shareholders on the website of the Company (www.noxxon.com).
These documents will also be made available to shareholders and persons entitled to attend the AGM, in the offices of the Company in Germany (Max-Dohrn-Straße 8-10, 10589 Berlin), and a copy will be provided free of charge upon request.
In accordance with Dutch law, the Board of directors has decided to draw up the list of persons entitled to participate in and vote at the AGM 28 days before the AGM. May be authorized to participate and vote at the AGM, the persons listed as shareholders on the records maintained by intermediaries, members (indirect) Euroclear France on the date of 30 may 2017 (the ” record date “) after recognition of all entries in the register, the debit and credit, on the date of closing of the registers.
About NOXXON
NOXXON Pharma N. V. is a biopharmaceutical company developing mainly in treatments against cancer. The goal of NOXXON is to significantly improve the effectiveness of cancer treatments, including the approaches to immuno-oncology (inhibitors of checkpoint immune) and current treatment the most common management (chemotherapy and radiotherapy). The platform of Spiegelmers of NOXXON has enabled the development of a select portfolio of product candidates at the clinical stage, in which its candidate anticancer drug lighthouse, NOX-A12 which is the subject of a collaboration in immuno-oncology with Merck & Co. Inc / MSD (NYSE:MRK) to conduct a clinical study of NOX-A12 is associated with the Keytruda® (pembrolizumab) in pancreatic cancer and colorectal cancer. NOXXON is backed by international investors of repute, including TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, DEWB, NGN and Seventure. Its headquarters are located in Amsterdam, the netherlands and its offices in Berlin, Germany. More information can be found on www.noxxon.com.
Download the free guide
Boost your gains
